CTRI/2024/04/066016招募中1 期
A Phase 1b, Single Arm, Multi-center, Open-label, Dose-escalation Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients with Invasive Fungal Infection - nil
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Biosergen AS
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age greater than 18 years.2. Able to provide written informed consent or have a legally authorized representative that can provide informed consent in case of incapacitation.3. Diagnosed by Investigator to have an IFI.Proven IFIs as defined in the 2020 consensus definitions by the European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC). Probable or possible IFIs can be included using the EORTC/MSGERC criteria or other established criteria. Protocol Number: BSG-1.02 Biosergen AS Confidential Protocol Version 1.0 Page 16 The inclusion of patients with IFI caused by, eg, Aspergillus spp and Candida spp, is preferred as these species are generally known to be responsive to a lower dose than other species, eg, Mucor mycosis spp. 4. IFI patients with mild to moderate renal impairment or IFI patients requiring an alternative treatment as current treatment cannot be continued due to any of the following: a) Failure with one first-line agent, defined as either Radiologic progression or Increase in serologic markers such as galactomannan antigen or beta-D-glucan or Failure of clearance of cultures or Progression or lack of improvement in a clinically appropriate timeframe of clinical symptoms attributed to IFI.b) Inability to tolerate AmB, as defined by at least one of the following i. Nephrotoxicity with either: 1.5 mg/dL increase in creatinine from baseline or 50% increase in creatinine from baseline ii. Contraindication to use AmB with either:Persistent hypokalemia or hypomagnesemia while on AmB despite appropriate electrolyte replacement c) Documented in vitro resistance to first-line antifungal therapy (ie fluconazole resistance in Candida auris) d) Treatment-limiting drug-drug interactions prohibiting the use of antifungals (azoles and echinocandins) such as concurrent rifampcin, rifabutin, phenytoin, carbamazepine, bedaqualine, quetiapine and others according to the antifungal interactions database(https://www.antifungalinteractions.org) or the patient is on any treatment prohibiting the use of standard antifungal agent such as azoles, echinocandins, amphotericin B, etc 5. Patient requiring not more than 28 days of antifungal therapy as per Investigator opinion as per the institutional guidance.
排除标准
- •1. Patient has a known hypersensitivity or severe infusion-related reaction to any polyene drug.
- •2. Infection caused by a known or suspected organism with intrinsic resistance to AmB.
- •3. Concurrent use of another investigational agent within 30 days of enrollment.
- •4. Chronic kidney disease with estimated glomerular filtration rate (eGFR) less than 30 mL/min or dialysis. Patients with acute kidney injury with eGFR less than 30 mL/min and improving creatinine level can be included as judged by the Investigator.
- •Note: Patients may be rescreened within 48 hours if laboratory values are found to be abnormal.
- •5. Has liver enzyme results (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) greater than 5 times the upper limit of normal.
- •Note: Patients may be rescreened within 48 hours if laboratory values are found to be abnormal.
- •6. Has a bilirubin level greater than 5 times the upper limit of normal.
- •Note: Patients may be rescreened within 48 hours if laboratory values are found to be abnormal.
- •7. Patients who have an ejection fraction less than 25% of predicted.
- •8. Currently pregnant or planning on getting pregnant while on study (details of contraception guidance are provided in Section 13).
- •9. Breastfeeding.
- •10. Patients not likely to survive a minimum of 28 days from start of screening.
- •11. Patient receiving prohibited medications.
- •12. Patient is an abuser of alcohol or medication.
- •13. Patient is unlikely to comply with protocol requirements.
- •14. Patients testing positive for HIV.
- •15. Patients with malignancy.
- •16. The Investigator is of the opinion the patient should not participate in the study.
- •17. If participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study.
研究者
相似试验
进行中（未招募）
1 期
Open-label Phase 1b study to evaluate safety and efficacy of ELA026 in Adults and Adolescents participants with sHLH.sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients require immediate and aggressive treatment with intensive care. Clinically, patients present with fever, hepatomegaly, pancytopenia, splenomegaly, hypotension, and coagulopathy. It is difficult to assess the true epidemiology of HLH due to the rarity of the condition.EUCTR2021-001387-20-ITElectra Therapeutics, Inc.24
进行中（未招募）
1 期
Open-label Phase 1b study to evaluate safety and efficacy of ELA026 in Adults and Adolescents participants with sHLH.sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients require immediate and aggressive treatment with intensive care. Clinically, patients present with fever, hepatomegaly, pancytopenia, splenomegaly, hypotension, and coagulopathy. It is difficult to assess the true epidemiology of HLH due to the rarity of the condition.MedDRA version: 20.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 21.1Level: PTClassification code 10058092Term: Multi-organ disorderSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2021-001387-20-ESElectra Therapeutics, Inc.24
进行中（未招募）
1 期
Open-label Phase 1b study to evaluate safety and efficacy of ELA026 in Adults and Adolescents participants with sHLH.sHLH is a rare and life-threatening inflammatory syndrome characterized by dysregulated immune function. The disease is associated with a massive systemic inflammatory response for which patients require immediate and aggressive treatment with intensive care. Clinically, patients present with fever, hepatomegaly, pancytopenia, splenomegaly, hypotension, and coagulopathy. It is difficult to assess the true epidemiology of HLH due to the rarity of the condition.MedDRA version: 20.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 21.1Level: PTClassification code 10058092Term: Multi-organ disorderSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2021-001387-20-NLElectra Therapeutics, Inc.24
终止
1 期
An open-label, single-arm, phase I/II, multicentre study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with unresectable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.ACTRN12615000292572Melanoma and Skin Cancer Trials10
进行中（未招募）
1 期
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute Myeloid Leukemia who are 60 Years or Older - The BATTLE StudyAcute Myeloid LeukemiaEUCTR2017-002237-29-SKBioLineRx, Ltd.60